Fig. 1From: Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational studyFlow chart of the study cohort. LHID Longitudinal Health Insurance Database, ACS acute coronary syndrome, Met metformin, SU sulphonylureas, AGI alpha-glucosidase inhibitor, TZD thiazolidinediones, DPP-4I dipeptidyl peptidase-4 inhibitorBack to article page